Breast density on mammography is a well-documented risk factor for a future breast cancer diagnosis.1 This association, and the desire to empower women regarding knowledge of their individualized breast cancer risk, has motivated several dozen states to enact legislation mandating patient notification of mammographic density, and in February 2019, federal law directed the US Food and Drug Administration to oversee a mammographic density–reporting process for the entire country.2 Approximately 40% to 50% of women in the United States will be found to have heterogeneously or extremely dense breasts, and this frequency has remained stable despite incorporation of advances in screening mammography, such as digital breast tomosynthesis.3 A formidable outstanding challenge, therefore, is for clinicians and patients to interpret this information and incorporate it into follow-up health care.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Newman LA, Yip C. Options for Addressing the Dilemma of Managing Dense Breasts. JAMA Surg. 2020;155(4):279–280. doi:10.1001/jamasurg.2020.0280
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.